文献速递青光眼

红景天苷对小梁网细胞细胞外基质表达及小鼠眼内压的影响

Effects of Salidroside on Trabecular Meshwork Cell Extracellular Matrix Expression and Mouse Intraocular Pressure.
PubMed 文献 · Invest Ophthalmol Vis Sci · 2019-01-01

本研究探讨红景天苷能否抑制TGF-β2诱导的人小梁网细胞细胞外基质(FN、COL-IV、LN)表达,并观察其对小鼠TGF-β2诱导性高眼压的作用。结果显示30 μM红景天苷可显著且完全逆转TGF-β2诱导的ECM表达升高;每日腹腔注射40 mg/kg红景天苷(第0天或第14天开始)显著降低小鼠TGF-β2诱导的高眼压,而对对照眼眼压无影响。作者认为该酚苷可能作为POAG的新型治疗手段。

要点

  • 30 μM红景天苷显著且完全逆转TGF-β2诱导的人小梁网细胞FN、COL-IV、LN表达升高。
  • 每日腹腔注射40 mg/kg红景天苷(第0天或第14天开始)显著降低小鼠TGF-β2诱导的高眼压。
  • 红景天苷对对照眼眼压无影响;作者认为其可能作为POAG的新型治疗手段。

核心结论

  • 红景天苷能减轻TGF-β2诱导的培养人小梁网细胞ECM表达,并降低小鼠TGF-β2诱导的高眼压,作者认为该酚苷可能作为POAG的新型治疗手段。

研究设计与样本

  • 体外研究:人小梁网细胞经5 ng/mL TGF-β2刺激48小时后,用红景天苷处理24小时,以定量PCR、Western blot和免疫细胞化学评估FN、COL-IV和LN表达。
  • 动物实验:BALB/cJ小鼠单眼玻璃体内注射编码TGF-β2生物活性突变体的腺病毒载体(Ad.hTGF-β2226/228)诱导高眼压,未注射的对侧眼或注射Ad.Empty的眼为对照,每日腹腔注射40 mg/kg红景天苷,用TonoLab回弹式眼压计测量清醒小鼠眼压。

主要发现

  • 在培养的人小梁网细胞中,TGF-β2处理使FN、COL-IV和LN表达升高(定量PCR、Western blot和免疫细胞化学评估),30 μM红景天苷显著且完全逆转上述升高。
  • 每日腹腔注射40 mg/kg红景天苷,无论从第0天(与Ad.hTGF-β2226/228注射同日)还是从第14天开始,均显著降低小鼠TGF-β2诱导的高眼压。
  • 红景天苷对对照眼的眼压无影响。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Excessive accumulation of extracellular matrix (ECM) in the trabecular meshwork (TM) reduces aqueous humor outflow, which likely contributes to elevation of IOP in primary open-angle glaucoma (POAG). Salidroside, a phenolic glycoside isolated from Rhodiola rosea is reported to prevent profibrotic responses by inhibiting Smad signaling pathway activated by TGF-β in liver, lung, and kidney tissues. We tested if salidroside can (1) inhibit TGF-β2-induced ECM expression in cultured human TM cells, and (2) lower TGF-β2-induced ocular hypertension in the mouse. METHODS: Cultured human TM cells stimulated with 5 ng/mL TGF-β2 for 48 hours were treated with salidroside for 24 hours. The expressions of fibronectin (FN), collagen type IV (COL-IV), and laminin (LN) were evaluated by quantitative PCR, Western blot, and immunocytochemistry. BALB/cJ mice were injected intravitreally with an adenoviral vector encoding a bioactive mutant of TGF-β2 (Ad.hTGF-β2226/228) in one eye to induce ocular hypertension, with the uninjected contralateral or Ad.Empty-injected eyes serving as controls. Mice were treated with a daily intraperitoneal injection of 40 mg/kg salidroside. Conscious mouse IOP values were measured using a TonoLab rebound tonometer. RESULTS: In cultured human TM cells, treatment with TGF-β2 increased expressions of FN, COL-IV, and LN, as assessed by quantitative PCR, Western blotting, and immunocytochemistry, all of which were significantly and completely ameliorated by 30 μM salidroside. Daily intraperitoneal injections of salidroside (40 mg/kg), starting either at day 0 (same day as Ad.hTGF-β2226/228 injection) or at day 14, significantly lowered TGF-β2-induced ocular hypertension in the mouse. In contrast, salidroside did not affect IOP of control eyes. CONCLUSIONS: These results demonstrated that salidroside is capable of minimizing TGF-β2-induced ECM expression in cultured human TM cells. It also reduced TGF-β2-induced ocular hypertension in the mouse. These findings indicate that this phenolic glycoside may be useful as a novel treatment for POAG.

来源:Invest Ophthalmol Vis Sci,查看原文。版权归原作者所有。

引用

  1. Fan Y, Guo L, Wei J, et al. Effects of Salidroside on Trabecular Meshwork Cell Extracellular Matrix Expression and Mouse Intraocular Pressure. Invest Ophthalmol Vis Sci. 2019. PMID: 31091314. doi:10.1167/iovs.19-26585

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。